| pubmed-article:11396631 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11396631 | lifeskim:mentions | umls-concept:C0699791 | lld:lifeskim |
| pubmed-article:11396631 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:11396631 | lifeskim:mentions | umls-concept:C0178874 | lld:lifeskim |
| pubmed-article:11396631 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11396631 | pubmed:dateCreated | 2001-6-8 | lld:pubmed |
| pubmed-article:11396631 | pubmed:abstractText | CD44 is a group of cell surface molecules involved in cell-cell and cell-matrix interactions. CD44 spliced variants (CD44V) have been found to enhance the metastatic potential of rat tumors. Tumors from the breast, colon, and thyroid express many alternatively spliced products; nonneoplastic tissues do not. Some authors suggest that CD44V5 and V6 may play a role in gastric carcinoma. The aim of the current study was to investigate the role of CD44V6 as a prognostic marker and predictor of metastatic potential in gastric carcinomas. One hundred fifty-five cases of gastric adenocarcinomas were studied: 36 cases of early (EGC), 19 cases of intermediate (MGC), and 100 cases of advanced gastric adenocarcinomas (AGC). A monoclonal antibody against CD44V6 (R&D) was used. CD44V6 expression was positively correlated with advanced stage (P = 0.05). Strong positivity was only detected in those cases of AGC with metastases. Patients with CD44V6 positive tumors revealed a lower 3- and 5-year survival rate (P = 0.0002). Immunohistochemical detection of CD44V6 could now be used as an indicator of tumor progression in biopsies of patients with gastric carcinoma. | lld:pubmed |
| pubmed-article:11396631 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11396631 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11396631 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11396631 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11396631 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11396631 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11396631 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11396631 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11396631 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11396631 | pubmed:issn | 1541-2016 | lld:pubmed |
| pubmed-article:11396631 | pubmed:author | pubmed-author:GraciEE | lld:pubmed |
| pubmed-article:11396631 | pubmed:author | pubmed-author:XiePP | lld:pubmed |
| pubmed-article:11396631 | pubmed:author | pubmed-author:LeaderM BMB | lld:pubmed |
| pubmed-article:11396631 | pubmed:author | pubmed-author:GaoQ YQY | lld:pubmed |
| pubmed-article:11396631 | pubmed:author | pubmed-author:GallagherM... | lld:pubmed |
| pubmed-article:11396631 | pubmed:author | pubmed-author:CurranB TBT | lld:pubmed |
| pubmed-article:11396631 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11396631 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:11396631 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11396631 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11396631 | pubmed:pagination | 138-42 | lld:pubmed |
| pubmed-article:11396631 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:meshHeading | pubmed-meshheading:11396631... | lld:pubmed |
| pubmed-article:11396631 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11396631 | pubmed:articleTitle | CD44V6 in gastric carcinoma: a marker of tumor progression. | lld:pubmed |
| pubmed-article:11396631 | pubmed:affiliation | Department of Pathology, Royal College of Surgeons in Ireland, St Stephen's Green. | lld:pubmed |
| pubmed-article:11396631 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11396631 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
